GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine based on Modified Vaccinia Ankara (MVA) vector technology, currently in multiple Phase 2 trials and a BARDA-funded Phase 2b trial. Other programs include Gedeptin for head and neck cancer, GEO-MVA for Mpox/smallpox, and preclinical vaccines for Ebola, Marburg, and Zika.
Q2 FY2026 — expected 2026-09-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-27 | 2024-12-31 | 0001437749-25-009614 | EDGAR | 40K words |
| 2024-02-29 | 2023-12-31 | 0001437749-24-006086 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001437749-23-007636 | EDGAR | — |
| 2022-03-09 | 2021-12-31 | 0001437749-22-005677 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001437749-21-006906 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001437749-20-006029 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001437749-19-005682 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001437749-18-005301 | EDGAR | — |
| 2017-03-24 | 2016-12-31 | 0001437749-17-005201 | EDGAR | — |
| 2016-03-16 | 2015-12-31 | 0001437749-16-027776 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034811 | EDGAR | 12K words |
| 2025-07-28 | 2025-06-30 | 0001437749-25-023651 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001437749-25-014083 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001437749-24-034530 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001437749-24-024867 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001437749-24-016605 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001437749-23-030926 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001437749-23-022775 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001437749-23-012551 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001437749-22-026579 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001437749-22-018639 | EDGAR | — |
| 2022-04-27 | 2022-03-31 | 0001437749-22-009862 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001437749-26-010733 | EDGAR | 9K words |
| 2026-02-17 | 0001437749-26-004392 | EDGAR | — |
| 2026-01-12 | 0001437749-26-001113 | EDGAR | — |
| 2025-12-22 | 0001437749-25-038547 | EDGAR | — |
| 2025-11-26 | 0001437749-25-036447 | EDGAR | — |
| 2025-11-13 | 0001437749-25-034903 | EDGAR | — |
| 2025-09-30 | 0001437749-25-030125 | EDGAR | — |
| 2025-08-01 | 0001437749-25-024389 | EDGAR | — |
| 2025-07-29 | 0001437749-25-023689 | EDGAR | — |
| 2025-07-02 | 0001437749-25-021990 | EDGAR | — |
397 total filings indexed. 365 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000832489 |
| Ticker | GOVX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.geovax.com |
| Listed | 1995-02-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report